These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 6433878)

  • 1. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia].
    Schimpf K
    Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the transmission of hepatitis by clotting factor concentrates.
    Tabor E
    Scand J Haematol Suppl; 1984; 40():303-8. PubMed ID: 6433456
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
    Pierce GF; Lusher JM; Brownstein AP; Goldsmith JC; Kessler CM
    JAMA; 1989 Jun; 261(23):3434-8. PubMed ID: 2498537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 6. Addition of hepatitis-B immunoglobulin to clotting factors.
    Smit Sibinga CT; Das PC; Nieweg HO
    Lancet; 1980 Sep; 2(8193):537. PubMed ID: 6105586
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute hepatitis non-A, non-B following administration of factor VIII concentrates.
    Norkrans G; Widell A; Teger-Nilsson AC; Kjellman H; Frösner G; Iwarson S
    Vox Sang; 1981 Sep; 41(3):129-33. PubMed ID: 6800131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hemophilia in children].
    Stucchi C; Giovanniello A; Dozzi M; Careddu P; Carnelli V
    Pediatr Med Chir; 1989; 11(6):607-15. PubMed ID: 2517639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 10. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders: a preliminary report of an antigen/antibody system.
    Bamber M; Murray A; Kernoff PB; Thomas HC
    Med Lab Sci; 1981 Oct; 38(4):373-8. PubMed ID: 6799726
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemophilia and acquired immunodeficiency].
    Allain JP
    Rev Prat; 1989 Dec; 39(30):2674-7. PubMed ID: 2515581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-A, non-B hepatitis in hemophilic patients with inhibitor treated with activated prothrombin complex concentrates: lack of correlation with an antigen possibly related to non-A, non-B hepatitis.
    Allain JP; Duermeijer W; Hellings JA; Gazengel C; Laurian Y; Verroust F
    Vox Sang; 1984; 47(1):47-53. PubMed ID: 6204454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive liver disease in haemophilia: an understated problem?
    Hay CR; Preston FE; Triger DR; Underwood JC
    Lancet; 1985 Jun; 1(8444):1495-8. PubMed ID: 2861420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prevention of liver disease in the hemophilic child].
    Carnelli V; Serafini I; Simoni L; Moroni GA; Giulotto P; Colombo M
    Pediatr Med Chir; 1983; 5(3):41-7. PubMed ID: 6417626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.